30 October 2017 – Global efforts to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2017, released by WHO today. Despite these achievements, the latest picture is grim. TB remains the top infectious killer in 2016. TB is also the main cause of deaths related to antimicrobial resistance and the leading killer of people with HIV. Progress in most countries is stalling and is not fast enough to reach global targets or close persistent gaps in TB care and prevention.
Use this document to find out where you must be tested for tuberculosis (TB) if you want to come to the UK for more than 6 months and are a resident of China. Find the location of approved testing centres in China.
22 June 2017 – The World Health Organization (WHO) released a new information note on “Considerations for adoption and use of multidisease testing devices in integrated laboratory networks”. The document, jointly prepared by the Global TB Programme and the Department of HIV and Global Hepatitis Programme, provides a strategic overview of key implementation considerations for diagnostic integration using testing devices for tuberculosis (TB), HIV and viral hepatitis.
Activities of the Strategic and Technical Advisory Group for TB (STAG-TB), Task Force on TB Impact Measurement, Latent TB Infection Task Force, HIV/TB Task Force and the Task Force for New Drug Policy Development.
Essay on Medicine. Research Paper on Tuberculosis
Tuberculosis is a treatable airborne infectious disease that kills almost 2 million people every year. Multidrug-resistant (MDR) tuberculosis — by convention, a disease caused by strains of Mycobacterium tuberculosis that are resistant to isoniazid and rifampin, the backbone of first-line antituberculosis treatment — afflicts an estimated 500,000 new patients annually. Resistance to antituberculosis agents has been studied since the 1940s; blueprints for containing MDR tuberculosis were laid out in the clinical literature and in practice, in several settings, more than 20 years ago. Despite the enormity of the threat, investments to contain the epidemic and to cure infected patients have been halting and meager when compared, for example, with those made to address the acquired immunodeficiency syndrome (AIDS) pandemic. In this essay we seek to elucidate the reasons for the anemic response to drug-resistant tuberculosis by examining the recent history of tuberculosis policy.
Sample research paper on Tuberculosis
Blumberg HM, Leonard MK, Jasmer RM (2005). Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 293 (22): 2776-84.
Dormandy, Thomas (2000). The White Death. New York: New York University Press.
Joint Tuberculosis Committee of the British Thoracic Society (2000). Control and prevention of tuberculosis in the United Kingdom: Code of practice 2000. Thorax 55 (11): 887-901.
Kidder, Tracy (2004). Mountains beyond mountains: A nonfiction account of treating TB in Haiti, Peru, Russia, and elsewhere. New York: Random House Trade Paperbacks.
Lawlor, Clark (2007). Consumption and Literature. Basingstoke: Palgrave Macmillan.
Custom Pulmonary Tuberculosis Essay - …
The failure of short-course chemotherapy against MDR tuberculosis, though unsurprising clinically, was difficult politically. In Peru, for example, a campaign to promote the DOTS strategy had been so successful in making short-course chemotherapy available that the country's leaders elevated it as a point of national pride. Peru emerged as a crucible for debates about the treatment and management of MDR tuberculosis in poor countries. In 1995, an outbreak in a shantytown in the northern reaches of Lima was identified. Many patients were infected with strains found to have broad-spectrum resistance to first-line drugs. Nongovernmental organizations worked with the Peruvian Health Ministry to apply the standard-of-care treatment used in New York City and elsewhere in the United States. The strategy was modified to provide community-based care, with good results. After arguing that the DOTS strategy alone could rein in the mutant bacteria, the WHO and other international public health authorities advised the Peruvian government to adopt a low-cost, standardized regimen for the treatment of MDR tuberculosis rather than protocols based on the results of drug-susceptibility testing. In the absence of tailored therapy, many hundreds of deaths occurred among some of Lima's poorest people. As expected, amplification of drug resistance was documented.